Dr. Jorge Latoni Maldonado, Plastic Surgery Medicare: Medicare Enrolled Practice Location: #27 Nelson Perea Norte S-15, Doctors Center, Mayaguez, PR 00682 Phone: 787-831-1000 Fax: 787-831-1014 |
Gustavo A Colberg, M.D. Plastic Surgery Medicare: Medicare Enrolled Practice Location: 351 Hostos Ave, Medical Emporium Suite 209, Mayaguez, PR 00680 Phone: 787-805-3232 Fax: 787-805-8140 |
News Archive
French researchers led by first author Abdallah Al-Salameh from the Department of Endocrinology, Diabetes Mellitus and Nutrition, Amiens University Hospital, Amiens, France, have published findings of their study titled, "The association between body mass index class and coronavirus disease 2019 outcomes," in the latest issue of the International Journal of Obesity.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments, has announced its decision to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its industrial development and production facility in Martigny (Valais, Switzerland), through acquisition of industrial high-value added activities or companies in the pharmaceutical, biotech or medtech field.
A new study shows that combining a technology called optical tomography with standard ultrasound imaging can help distinguish early-stage breast cancer from non-cancerous lesions-and potentially reduce the number of breast biopsies performed. The study appears in the October issue of the journal Radiology.
Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen's proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.
Octapharma USA has received confirmation of orphan drug exclusivity from the U.S. Food and Drug Administration for wilate (von Willebrand Factor/Factor VIII Concentrate, Human), the replacement therapy developed specifically for von Willebrand Disease. The approval comes from the FDA Office of Orphan Products Development, which helps to advance the development of products that demonstrate promise for the treatment of rare diseases.
› Verified 2 days ago